2. Academic Validation
  3. Imidazo Pyrimidine Compounds for the Inhibition of Oncogenic KRAS Mutations in Cancer Therapy

Imidazo Pyrimidine Compounds for the Inhibition of Oncogenic KRAS Mutations in Cancer Therapy

  • ACS Med Chem Lett. 2025 Oct 30;16(11):2194-2196. doi: 10.1021/acsmedchemlett.5c00628.
Xiaoyan Li 1,  Steven H Liang 1
Affiliations

Affiliation

  • 1 Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, Atlanta, Georgia 30322, United States.
PMID: 41256973 DOI: 10.1021/acsmedchemlett.5c00628
Abstract

This highlight outlines the development of novel imidazo-pyrimidine compounds as potent inhibitors targeting oncogenic KRAS mutations, including G12D, G12V, and G12C. The disclosure includes details on synthetic methods, biological evaluation, metabolic stability, and pharmaceutical compositions.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z